

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

LISTING OF CLAIMS:

1. (currently amended) A reconstituted viral membrane, the lipid bilayer of which comprises a fusion protein of a virus, an amphiphilic adjuvant and, optionally, a further antigen, whereby:

(a) the lipid bilayer has a lipid composition that is compatible with fusion, induced by the fusion protein, of the viral membrane with the membrane of a cell that can be fused with the virus from which the fusion protein is derived;

(b) the fusion protein and the amphiphilic adjuvant interact with the hydrophobic interior of the lipid bilayer; and,

(c) the fusion protein, the amphiphilic adjuvant and the optional further antigen are not covalently linked; and
wherein the amphiphilic adjuvant is a lipopeptide.

2. (original) A reconstituted viral membrane according to claim 1, wherein the lipid bilayer comprises natural lipids of a viral membrane.

3. (canceled)

4. (previously presented) A reconstituted viral membrane according to claim 1, wherein the amphiphilic adjuvant is a ligand for a mammalian Toll-like receptor.

5. (currently amended) A reconstituted viral membrane according to claim ~~[[3]]~~ 1, wherein the lipopeptide is selected from the group consisting of: *N*-palmitoyl-S-2,3(bispalmitoyloxy)-propyl-cysteiny-l-seryl-serine, S-2,3(bispalmitoyloxy)-propyl-cysteiny-l-seryl-serine, *N*-palmitoyl-S-2,3(bispalmitoyloxy)-propyl-cysteiny-l-seryl-(lysil)₃-lysine, S-2,3(bispalmitoyloxy)-propyl-cysteiny-l-seryl-(lysil)₃ -lysine, *N*-palmitoyl-S-2,3(bisoleoyloxy)-propyl-cysteiny-l-seryl-(lysil)₃-lysine, S-2,3(bisoleoyloxy)-propyl-cysteiny-l-seryl-serine-(lysil)₃ -lysine, *N*-palmitoyl-S-2,3(bismyristoyloxy)-propyl-cysteiny-l-seryl-(lysil)₃-lysine, S-2,3(bismyristoyloxy)-propyl-cysteiny-l-seryl-(lysil)₃ -lysine, *N*-palmitoyl-S-3(palmitoyloxy)-propyl-cysteiny-l-seryl-(lysil)₃ -lysine and *N*-palmitoyl-S-2,3 hydroxy-propyl-cysteiny-l-seryl-(lysil)₃-lysine, *N*-palmitoyl-S-2,3(bispalmitoyloxy)-propyl-cysteiny-l-seryl-(prolyl)₃-proline, *N*-palmitoyl-S-2,3(bispalmitoyloxy)-propyl-cysteiny-l-seryl-(glutaminyl)₃-glutaminic acid.

6. (canceled)

7. (currently amended) A reconstituted viral membrane according to claim 1, wherein at least one of a fusion protein of a virus or a further antigen ~~the antigen~~ is an integral membrane protein.

8. (currently amended) A reconstituted viral membrane according to claim 1, wherein at least one of a fusion protein of a virus or a further antigen ~~the antigen~~ is a viral antigen.

9. (currently amended) A reconstituted viral membrane according to claim 8, wherein at least one of a fusion protein of a virus or a further antigen ~~the antigen~~ is from an influenza virus.

10. (currently amended) A reconstituted viral membrane according to claim 9, wherein at least one of a fusion protein of a virus or a further antigen ~~the antigen~~ is a hemagglutinin (HA), a neuraminidase (NA) or an M2 protein.

11. (withdrawn, currently amended) A reconstituted viral membrane according to claim 8, wherein at least one of a fusion protein of a virus or a further antigen ~~the antigen~~ is derived from a virus selected from the group consisting of Retroviridae, rubellavirus, Paramyxoviridae, Flaviviridae, Herpesviridae, Bunyaviridae, Arenaviridae, Hantaviridae,

Coronaviridae, Papovaviridae, Rhabdoviridae, Coronaviridae, Alphaviridae, Arteriviridae, Filoviridae, Arenaviridae, poxviridae, and African swine fever virus.

12. (withdrawn, currently amended) A reconstituted viral membrane according to claim 1, wherein the further antigen ~~the antigen~~ is derived from a parasite, a bacterium, a fungus, a yeast, or wherein the further antigen ~~the antigen~~ is a tumor-specific antigen.

13. (canceled)

14. (previously presented) A pharmaceutical composition comprising a reconstituted viral membrane as defined in claim 1 and a pharmaceutically acceptable carrier.

15. (original) A pharmaceutical composition according to claim 14, whereby the composition is suitable for intranasal, oral or parenteral administration.

16. (canceled)

17. (previously presented) A reconstituted viral membrane according to claim 2, wherein the amphiphilic adjuvant is a ligand for a mammalian Toll-like receptor.

18. (canceled)

19. (currently amended) A reconstituted viral membrane according to claim 2, wherein at least one of a fusion protein of a virus or a further antigen ~~the antigen~~ is an integral membrane protein.

20. (canceled)

21. (currently amended) A reconstituted viral membrane according to claim 4, wherein at least one of a fusion protein of a virus or a further antigen ~~the antigen~~ is an integral membrane protein.

22. (new) A reconstituted viral membrane according to claim 5, wherein at least one of a fusion protein of a virus or a further antigen is a hemagglutinin (HA), a neuraminidase (NA) or an M2 protein.

23. (new) A reconstituted viral membrane according to claim 22, wherein the fusion protein of a virus is a hemagglutinin (HA) and the further antigen is a neuraminidase (NA).

24. (new) A reconstituted viral membrane according to claim 22, wherein the fusion protein of a virus is a neuraminidase (NA) and the further antigen is a hemagglutinin (HA).